Mersana Therapeutics(MRSN)2025-03-03 12:27Financial Performance - Net loss for Q4 2024 was 0.11 per share, an improvement from a net loss of 0.16 per share, in Q4 2023[10] - Full year 2024 collaboration revenue was 36.9 million in 2023, driven by milestone payments from the Johnson & Johnson collaboration[14] - Net loss for the full year 2024 was 0.56 per share, compared to a net loss of 1.48 per share, in 2023[14] Revenue and Expenses - Collaboration revenue for Q4 2024 was 10.7 million in Q4 2023, primarily due to increased revenue from collaborations with Johnson & Johnson, Merck KGaA, and GSK[10] - R&D expenses for Q4 2024 were 21.5 million in Q4 2023, with the increase attributed to costs for Emi-Le and XMT-2056[10] - R&D expenses for the full year 2024 were 148.3 million in 2023, due to reduced costs for discontinued programs and restructuring[14] - G&A expenses for the full year 2024 were 59.5 million in 2023, reflecting reduced consulting fees and employee compensation[14] Cash Position - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $134.6 million, with expectations to support operations into 2026[10] Clinical Development - Mersana plans to present additional Phase 1 clinical data for Emi-Le and XMT-2056 in 2025, with ongoing patient enrollment in clinical trials[6][8] - The company received a second Fast Track designation for Emi-Le from the FDA, indicating progress in its clinical development efforts[4]